Clofarabine Active in a Broad Range of Hematologic Cancers; Data Presented at 10th European Haematology Association -EHA- Sympos
June 06 2005 - 7:00AM
Business Wire
Bioenvision (Nasdaq: BIVN) announced that clofarabine's potential
as the next generation of leukemia treatment was a focal point
during a symposium led by internationally renowned haematologists
from the MD Anderson Cancer Center, Houston, Texas, at the 10th
European Haematology Association (EHA) meeting in Stockholm,
Sweden. A main focus of attention at the symposium was
clofarabine's activity in leukaemia. Clofarabine has recently been
approved by the FDA for the treatment of relapsed/refractory acute
lymphoblastic leukaemia in pediatric patients. However, Dr. Stefan
Faderl, presented data at the meeting in which clofarabine was used
as first-line treatment of acute myeloid leukaemia (AML) in adults.
This Phase II, investigator-sponsored study was conducted at MDACC
and was presented for the first time in Europe. This study compared
clofarabine as a single agent versus clofarabine in combination
with low-dose ara-C in patients greater than or equal to 60 years
(median age 72 years) and showed that clofarabine as a single agent
achieved a CR of 45% (5/11) and clofarabine in combination with
low-dose ara-C achieved a CR of 60% (12/20). Professor Hagop
Kantarjian reviewed data from a small investigator-sponsored study
of clofarabine in high-risk myelodysplastic syndrome (MDS), in
which a complete response rate (CR + CRp) of 50% was observed, and
stated that clofarabine was one of the new agents that offered hope
for the future in MDS. Dr. William Plunkett referred to the ongoing
investigator-sponsored Phase I clinical study of clofarabine in
chronic lymphocytic leukaemia (CLL). He also presented data on the
accumulation and retention of clofarabine in lymphocytes from
patients with CLL and showed clofarabine to be far more active than
fludarabine or ara-C. In addition, Dr. Plunkett presented
experimental evidence for the synergistic effect of combining
clofarabine with a range of DNA-damaging agents and showed the
potential for clofarabine in combination regimens for the treatment
of both hematologic cancers and solid tumors. Each of the
investigator-sponsored studies referred to by Drs. Faderl,
Kantarjian and Plunkett have been conducted with the support of our
co-development partner, Genzyme Corporation (Nasdaq: GENZ). "We are
encouraged to see clofarabine being studied in a broad range of
hematologic cancers thereby enabling us to further build upon
clofarabine's commercial potential" said Dr Chris Wood, CEO and
Chairman of Bioenvision. About Clofarabine Clofarabine is a next
generation of the drug class, purine nucleoside analogs that
inhibit DNA production necessary for cancer cell growth.
Bioenvision and Genzyme are co-developing clofarabine. Bioenvision
holds an exclusive worldwide license to clofarabine (outside Japan
and Southeast Asia). Bioenvision granted an exclusive sublicense to
Genzyme to develop and commercialize clofarabine for cancer
indications in the United States and Canada. Bioenvision holds an
exclusive license in the US and Canada to all non-cancer
indications and an exclusive, irrevocable option to develop and
market clofarabine for all human applications in Japan and
Southeast Asia. Bioenvision originally obtained clofarabine
development and commercialization rights under patents held by
Southern Research Institute. Clofarabine has been granted orphan
drug designation for the treatment of adult and pediatric ALL and
AML in the U.S. and Europe. In the U.S., orphan drug status extends
market exclusivity for seven years. The FDA also recently granted
an additional six months market exclusivity to clofarabine under
the Best Pharmaceuticals for Children Act. In Europe, the
designation provides marketing exclusivity for 10 years. About
Bioenvision Bioenvision's primary focus is the acquisition,
development and distribution of compounds and technologies for the
treatment of cancer. Bioenvision has a broad pipeline of products
for the treatment of cancer, including: Clofarabine (in
co-development with Genzyme Corporation), Modrenal(R) (for which
Bioenvision has obtained regulatory approval for marketing in the
United Kingdom for the treatment of post-menopausal breast cancer
following relapse to initial hormone therapy), and other products
in clinical trials. Bioenvision is also developing anti-infective
technologies, including the OLIGON technology; an advanced
biomaterial that has been incorporated into various FDA approved
medical devices. For more information on Bioenvision please visit
our Web site at www.bioenvision.com. Certain statements contained
herein are "forward-looking" statements (as such term is defined in
the Private Securities Litigation Reform Act of 1995). Because
these statements include risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Specifically, factors that could cause
actual results to differ materially from those expressed or implied
by such forward-looking statements include, but are not limited to:
risks associated with preclinical and clinical developments in the
biopharmaceutical industry in general and in Bioenvision's
compounds under development in particular; the potential failure of
Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure
to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers,
licenses or strategic initiatives that change Bioenvision's
business, structure or projections; the development of competing
products; uncertainties related to Bioenvision's dependence on
third parties and partners; and those risks described in
Bioenvision's filings with the SEC. Bioenvision disclaims any
obligation to update these forward-looking statements.
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From May 2024 to Jun 2024
Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jun 2023 to Jun 2024